Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H8I3N2O4.Na |
Molecular Weight | 635.8954 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(=O)NC1=C(I)C(C([O-])=O)=C(I)C(NC(C)=O)=C1I
InChI
InChIKey=ZEYOIOAKZLALAP-UHFFFAOYSA-M
InChI=1S/C11H9I3N2O4.Na/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);/q;+1/p-1
Molecular Formula | Na |
Molecular Weight | 22.98976928 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C11H8I3N2O4 |
Molecular Weight | 612.9056 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00271Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00271
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety. A commonly used x-ray contrast medium. Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues.
CNS Activity
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=3198373
Curator's Comment: Diatrizoic acid was discovered in 1953 simultaneously and independently by Schering AG in Berlin and by Sterling-Winthrop in the USA.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Cystografin Approved UseRetrograde cystourethrography Launch Date1955 |
|||
Diagnostic | Gastrografin Approved UseGastrografin (DIATRIZOIC ACID) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). Launch Date1958 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.6 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
102 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Transcervical catheterization and cervical patency during the oestrous cycle in domestic cats. | 2001 |
|
The accordion sign at CT: report of a case of Crohn's disease with diffuse colonic involvement. | 2001 |
|
Temporary pancreatic duct occlusion by ethibloc: cause of microcirculatory shutdown, acute inflammation, and pancreas necrosis. | 2001 Apr |
|
Shielding effects of metallic encapsulations and radiographic contrast agents for catheter-based intravascular brachytherapy. | 2001 Apr-Jun |
|
Laparoscopic inflatable band with Roux-en-Y gastric bypass. | 2001 Aug |
|
The role of early radiological studies after gastric bariatric surgery. | 2001 Aug |
|
Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. | 2001 Dec |
|
A simple method for the identification and assay of iopamidol and iothalamate meglumine in pharmaceutical samples based on proton nuclear magnetic resonance spectroscopy. | 2001 Feb |
|
The selective adenosine A1 receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide deficiency. | 2001 Feb 23 |
|
Review of studies establishing the aging male spontaneously hypertensive rat as a detector and quantifier of the kidney toxicity of radiocontrast media and other chemicals. | 2001 Jan |
|
Evaluation of suspected appendicitis in children using limited helical CT and colonic contrast material. | 2001 Jan |
|
Rapid diagnosis of sigmoid volvulus with water soluble urografin in emergency service. | 2001 Nov |
|
Effect of ionic and nonionic contrast media on fibrinolysis in patients undergoing angiocardiography. | 2001 Oct |
|
Pseudomembranous colitis without diarrhea presenting clinically as acute intestinal pseudo-obstruction. | 2001 Sep |
|
Oesophageal rupture resulting from airbag deployment during a motor vehicle accident. | 2001 Sep |
|
[Which imaging in case of sigmoid diverticulitis? The value of ultrasound (Conventional B-mode in combination with hydrocolonsonography and colour flow Doppler) in comparison to the well-established modalities like contrast enema and helical computertomography]. | 2002 Apr |
|
Application of oral contrast media in coregistered positron emission tomography-CT. | 2002 Aug |
|
Emergency colonoscopy for distal intestinal obstruction syndrome in cystic fibrosis patients. | 2002 Aug |
|
Thumbprinting due to ischemic colitis in a patient on oral anticoagulation. | 2002 Aug-Sep |
|
The utility of contrast studies and drains in the management of patients after Roux-en-Y gastric bypass. | 2002 Feb |
|
Systemic platelet effects of contrast media: implications for cardiologic research and clinical practice. | 2002 Jan |
|
Contrast radiography and intestinal obstruction. | 2002 Jul |
|
Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media. | 2002 Jul |
|
Iodinated contrast medium-induced potassium release: the effect of mixing ratios. | 2002 Jul-Aug |
|
Type IV diaphragmatic hiatal hernia. | 2002 Jun-Jul |
|
Laparoscopic repair for perforated peptic ulcer: a randomized controlled trial. | 2002 Mar |
|
Do clinically relevant circulating concentrations of radiographic contrast agents inhibit platelet-dependent arterial thrombosis? | 2002 Mar 1 |
|
A case of gastric duplication evaluated by gastric emptying scintigraphy. | 2002 May |
|
Long-term survival of patients with stage IV hypopharyngeal cancer: impact of fundus rotation gastroplasty. | 2002 May |
|
New strategies in nonoperative management of meconium ileus. | 2002 May |
|
Jejunum free flap in hypopharynx reconstruction: case series. | 2002 May 10 |
|
The role of theophylline in contrast-induced nephropathy: a case-control study. | 2002 Nov |
|
Pressure-assisted micturating cystourethrography: reduction in duration of procedure and fluoroscopy time. | 2002 Nov |
|
The value of contrast radiology for postoperative adhesive small bowel obstruction. | 2002 Nov-Dec |
|
Venous port salvage utilizing low dose tPA. | 2002 Nov-Dec |
|
Chronic renal dysfunction late after liver transplantation. | 2002 Oct |
|
Renal chemoembolization with mitomycin c/Ethibloc: pharmacokinetics and efficacy in an animal model. | 2002 Sep |
|
The diagnostic yield of colonoscopy and the therapeutic value of intraduodenal amidotrizoic acid injection in intestinal Diphyllobothrium latum infection: report of a case. | 2002 Sep |
|
Ex vivo expansion of megakaryocyte progenitors from cryopreserved umbilical cord blood. A potential source of megakaryocytes for transplantation. | 2002 Sep |
|
[Fast method of labelling leukocytes with 99mTc HM PAO]. | 2002 Sep-Oct |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: For radiographic examination of segments of the gastrointestinal tract (Gastrografin) oral administration: adult oral dosage may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature of the examination and the size of the patient. For Enemas or Enterostomy Instillations: should be diluted when it is used for enemas and enterostomy instillations. When used as an enema, the suggested dilution for adults is 240 mL (88 g iodine) in 1,000 mL of tap water. http://www.drugs.com/pro/gastrografin.html
;
The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:45:31 GMT 2025
by
admin
on
Wed Apr 02 09:45:31 GMT 2025
|
Record UNII |
V5403H8VG7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C390
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
||
|
CFR |
21 CFR 522.563
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Diatrizoate
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
23672589
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
3321
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | RxNorm | ||
|
V5403H8VG7
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
m4263
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID7022912
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
DBSALT000267
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
737-31-5
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
212-004-1
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
SUB10547MIG
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
61815
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
DIATRIZOATE SODIUM
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | Description: A white powder; odourless or almost odourless. Solubility: Freely soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Radiocontrast medium. Storage: Sodium amidotrizoate should be kept in a well-closed container, protected from light. Requirements: Sodium amidotrizoate contains not less than 98.0% and not more than the equivalent of 102.0% of C11H8I3N2NaO4, calculated with reference to the anhydrous substance. | ||
|
V5403H8VG7
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
100000091989
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201220
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
C47981
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
8078
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
358
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
53692
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
PRIMARY | |||
|
24360-64-3
Created by
admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
No peak value listed on EP
|
||
|
IMPURITY -> PARENT |
No peak value listed in EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |